^
    24h
    Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=64, Suspended, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Feb 2026 --> Dec 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    temozolomide • vincristine • locnartecan (PEN-866)
    1d
    Targeting glycerophospholipid biosynthesis overcomes chemoresistance driven by SLFN11 loss in Ewing sarcoma. (PubMed, Cell Death Dis)
    Subsequently, targeting GPL biosynthesis (FSG67) restored DNA-damaging agent (SN-38) sensitivity in SLFN11-deficient EWS model, revealing a potential metabolic vulnerability to overcome chemoresistance. Furthermore, SLFN11 knockout tumors exhibited an elevated phosphocholine/glycerophosphocholine ratio, offering a potential non-invasive diagnostic biomarker.
    Journal
    |
    SLFN11 (Schlafen Family Member 11)
    1d
    OSE: Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence (clinicaltrials.gov)
    P=N/A, N=92, Completed, Gustave Roussy, Cancer Campus, Grand Paris | N=530 --> 92 | Recruiting --> Completed
    Trial completion • Enrollment change
    2d
    Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas (clinicaltrials.gov)
    P=N/A, N=98, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed
    Trial completion
    3d
    EMERGE 101: Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Jazz Pharmaceuticals | Trial completion date: Jun 2027 --> Apr 2028 | Trial primary completion date: Dec 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Zepzelca (lurbinectedin)
    3d
    Androgen Receptor Positive EWSR1::FEV-Rearranged Prostatic Ewing Sarcoma Mimicking High-Grade Neuroendocrine Carcinoma. (PubMed, Int J Surg Pathol)
    Immunostain for androgen receptor was strongly and diffusely positive in the primary tumor and in the nodal metastasis, which together with focal staining for NKX3.1 were suggestive of primary prostatic origin and invited consideration of androgen deprivation therapy. This report highlights a rare prostatic Ewing-family sarcoma harboring an EWSR1::FEV fusion and immunophenotypic features that mimic a neuroendocrine carcinoma.
    Journal
    |
    AR (Androgen receptor) • EWSR1 (EWS RNA Binding Protein 1) • CD99 (CD99 Molecule) • SYP (Synaptophysin) • NKX3-1 (NK3 homeobox 1)
    |
    AR positive
    3d
    ADER: Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Istituto Ortopedico Rizzoli | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    4d
    Tumor-activated dual metabolic nanomodulator turns over tolerogenic tumor control and unleashes systemic immune responses. (PubMed, J Nanobiotechnology)
    RAISE exhibited efficient tumor control, and when combined with anti-PD-1 immunotherapy, RAISE inhibited lung metastasis, generated systemic immune responses, and induced immune memory. Taken together, RAISE can be utilized to trigger long-term systemic antitumor immunity for improving tumor immunotherapy.
    Journal
    |
    ITGAE (Integrin Subunit Alpha E)
    4d
    Adamantinoma-like Ewing sarcoma of the parotid gland: A case report. (PubMed, J Clin Imaging Sci)
    Despite initial response, the patient experienced significant toxicities and eventually succumbed to disease-related complications. This case illustrates the challenges in diagnosing and managing rare parotid malignancies and highlights the importance of multidisciplinary care.
    Journal
    |
    FUS (FUS RNA Binding Protein)
    4d
    Primary Extracranial Ewing Sarcoma Complicated by Hemorrhagic Shock and Multimicrobial Infection: A Diagnostic and Therapeutic Challenge. (PubMed, Cureus)
    Despite the initiation of palliative chemotherapy, the patient experienced rapid tumor progression with recurrent hemorrhage, multiorgan failure, and death. This case highlights the rarity, aggressiveness, and diagnostic complexity of extracranial Ewing sarcoma, emphasizing the importance of a multidisciplinary approach and early molecular confirmation.
    Journal
    |
    EWSR1 (EWS RNA Binding Protein 1)
    6d
    A Phase II, Single-Center, Prospective, Open-Label Study Evaluating Three Combination Regimens in the Treatment of Refractory Advanced Ewing Sarcoma (ChiCTR2500114068)
    P=N/A, N=90, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
    New trial
    |
    temozolomide • Vizimpro (dacomitinib)
    6d
    Clinical Study on Spatiotemporal Fractionated Whole-Lung Irradiation with Helical Tomotherapy for Pulmonary Metastases from Ewing Sarcoma (ChiCTR2500113217)
    P=N/A, N=36, Not yet recruiting, Peking University Shougang Hospital; Peking University Shougang Hospital
    New trial